<DOC>
	<DOCNO>NCT01505894</DOCNO>
	<brief_summary>The primary objective trial investigate safety tolerability multiple dos BI 409306 healthy young elderly volunteer . The secondary objective explore pharmacokinetics pharmacodynamics multiple dos BI 409306 healthy young elderly volunteer</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Rising Doses</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test 2 . Age &gt; 21 Age &lt; 50 year young healthy volunteer Age &gt; 65 Age &lt; 80 year elderly healthy volunteer 3 . BMI &gt; 18.5 BMI &lt; 29.9 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation . 5 . For female subject : Female subject must surgically sterilize postmenopausal . Surgical sterilization hysterectomy must occur least 6 month prior screen . Menopausal woman must regular menstrual bleeding least 2 year prior screen . Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Surgery gastrointestinal tract ( except appendectomy ) 5 . Diseases central nervous system ( include limit kind seizure , stroke psychiatric disorder ) 6 . History evidence relevant orthostatic reaction ( drop systolic blood pressure ( SBP ) &gt; 20 mm Hg increase heart rate &gt; 30 bpm 2 minute stand relative supine data ) , faint spell blackout . 7 . Chronic relevant acute infection 8 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 9 . Intake drug within 14 day drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 10 . Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial 11 . Participation another trial investigational drug within four week prior administration trial 12 . Smoker ( &gt; 5 cigarette &gt; 1 cigar &gt; 1 pipes/day ) 13 . Inability refrain smoke trial day 14 . Alcohol abuse ( 20 g/day ) 15 . Drug abuse 16 . Blood donation ( 100 mL within four week prior administration trial ) 17 . Excessive physical activity ( within one week prior administration trial ) 18 . Any laboratory value outside reference range clinical relevance judgment investigator 19 . Inability comply dietary regimen trial site 20 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc F interval &gt; 430 m male &gt; 450 ms female ) ; 21 . A history additional risk factor TdP ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) ;</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>